Insulin efsitora alfa
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Insulin efsitora alfa
- homo sapiens insulin b chain y16 y 16 f25 h 25 tpkt27 30 gggg 27 30 1 30 fusion protein with diglycylseryltetraglycyl 31 37 insulin a chain i10 t 47 y14 d 51 n21 g 58 38 58 fusion protein with tris tetraglycylglutaminyl pentaglycyl 59 78 homo sapiens immunoglobulin heavy constant gamma 2 del ch1 hinge 7 12 ch2 ch3 k107 del 300 79 299 dimer 80 80 83 83 bisdisulfide expressed in cho cells alfa glycosylated
- Homo sapiens Insulin B-chain [Y16>Y(16), F25>H(25), TPKT27-30>GGGG(27- 30)] (1-30) fusion protein with diglycylseryltetraglycyl (31-37) Insulin A-chain [I10>T(47), Y14>D(51), N21>G(58)] (38-58) fusion protein with tris(tetraglycylglutaminyl)pentaglycyl (59-78) Homo sapiens Immunoglobulin heavy constant gamma 2 {del-CH1, hinge-(7-12), CH2, CH3[K107>del(300)]} (79-299), dimer (80-80':83-83')-bisdisulfide, expressed in CHO cells, alfa glycosylated
- Insulin [16-glutamic acid, 25-histidine, 27-glycine, 28-glycine, 29-glycine, 30- glycine] (human B-chain) fusion protein with peptide (synthetic 7-amino acid linker) fusion protein with insulin [47-threonine, 51-aspartic acid, 58-glycine] (human A-chain) fusion protein with peptide (synthetic 20-amino acid linker) fusion protein with immunoglobulin G2 (human Fc fragment), dimer
- insulin 16 glutamic acid 25 histidine 27 glycine 28 glycine 29 glycine 30 glycine human b chain fusion protein with peptide synthetic 7 amino acid linker fusion protein with insulin 47 threonine 51 aspartic acid 58 glycine human a chain fusion protein with peptide synthetic 20 amino acid linker fusion protein with immunoglobulin g2 human fc fragment dimer
- insulin efsitora alfa
- Insulin efsitora alfa
- Insulin Efsitora Alfa
- insulin efsitora alfa [INN]
- INSULIN EFSITORA ALFA [USAN]
- Insulin efsitora alfa [WHO-DD]
- insulin efsitora alfa inn
- insulin efsitora alfa usan
- insulin efsitora alfa who dd
- ly 3209590
- LY-3209590
- ly3209590
- LY3209590
- LY3209590 (Formulation 1)
- LY3209590 (Formulation 2)
- CAS registry numbers
- 2131038-11-2
- ChEMBL ID
- CHEMBL5095357
- FDA ingredient codes (UNII)
- OZ465SMQ28
- Status
- opinion
- Status date
- 25 Jun 2026
- Approved indications
- Treatment of type 2 diabetes mellitus
- Product number
- EMEA/H/C/006388
- Authorisation holder
- Eli Lilly Nederland B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Diabetes Mellitus
European medicines record
- First in class
- No
- Orphan designation
- No
- Drug name stem
- ef-
- Condition
- Diabetes Mellitus, Type 1
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005147
- Subject identifier
- D003922
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- NCT02942914
- NCT03367377
- NCT03603704
- NCT03736785
- NCT04276428
- NCT04450394
- NCT04957914
- NCT05275400
- NCT05462756
- NCT05596747
- NCT05662332
- NCT06169982
- NCT06362265
- NCT04450407
- NCT05463744
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (133)
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers
- A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers
- A Comparison of the Safety and Comfort of AC-170
- A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants
- A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes
- A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
- A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
- A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
- A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
- A Phase â…˘ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
- A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
- A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
- A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions
- A Relative Bioavailability Study of LY3209590 in Healthy Participants
- A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food
- A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food
In development for (2)
- Type 1 diabetes mellitus Phase 3
- Type 2 diabetes mellitus Phase 3